These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16892366)

  • 21. Modeling of the hERG K+ Channel Blockage Using Online Chemical Database and Modeling Environment (OCHEM).
    Li X; Zhang Y; Li H; Zhao Y
    Mol Inform; 2017 Dec; 36(12):. PubMed ID: 28857516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of hERG channel blockers using a decision tree.
    Gepp MM; Hutter MC
    Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
    Jo SH; Hong HK; Chong SH; Choe H
    Life Sci; 2008 Jan; 82(5-6):331-40. PubMed ID: 18191158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
    Rampe D; Murawsky MK; Grau J; Lewis EW
    J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hERG K+ channel: target and antitarget strategies in drug development.
    Raschi E; Vasina V; Poluzzi E; De Ponti F
    Pharmacol Res; 2008 Mar; 57(3):181-95. PubMed ID: 18329284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
    Kireeva N; Kuznetsov SL; Bykov AA; Tsivadze AY
    SAR QSAR Environ Res; 2013; 24(2):103-17. PubMed ID: 23152964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
    Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
    J Mol Cell Cardiol; 2004 May; 36(5):701-5. PubMed ID: 15135665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
    Du F; Babcock JJ; Yu H; Zou B; Li M
    PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models.
    Zhang X; Mao J; Wei M; Qi Y; Zhang JZH
    J Chem Inf Model; 2022 Apr; 62(8):1830-1839. PubMed ID: 35404051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Tobita M; Nishikawa T; Nagashima R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2886-90. PubMed ID: 15911273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
    Sanguinetti MC; Mitcheson JS
    Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
    Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.